Tyra Biosciences, Inc.
corporate_fare Company Profile
Tyra Biosciences, Inc. (NASDAQ:TYRA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for TYRA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 8/10, with 8 rated 8 or above. Recent SEC coverage for TYRA spans 8-K, SCHEDULE 13D/A, 424B5, FWP.
Recent high-impact activity:
- Tyra Biosciences Posts 74c Quarterly Loss, Cash of $700.5M
- Tyra Posts Q3 Loss of $51.1M, $700.5M Cash Funds Dabogratinib Through 2030
- RA Capital Discloses $200M Pre-Funded Warrant Purchase in Tyra's $400M Offering
- Tyra Biosciences Prices $400M Underwritten Offering at $22.03/Share
- Tyra Biosciences Finalizes $400M Underwritten Offering at $22.03/Share
Financial Snapshot
Short Interest & Short Volume
15.28 days to coverFINRA reported short interest of 9,901,757 shares in TYRA as of the October 30, 2026 settlement, a 4.3% increase from the prior period — about 15.3 days to cover at its recent average daily volume. On November 20, 2026, 73.8% of TYRA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for TYRA, detected from its recent SEC filings · based on capital-structure filings through 2026-09-14.
$400M Underwritten Offering Priced · Net Proceeds of $373.9M
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →